vs
FRANKLIN FINANCIAL SERVICES CORP（FRAF）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
FRANKLIN FINANCIAL SERVICES CORP的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.3M vs $19.6M），FRANKLIN FINANCIAL SERVICES CORP净利率更高（25.9% vs -177.4%，领先203.3%），FRANKLIN FINANCIAL SERVICES CORP同比增速更快（51.5% vs -11.5%），过去两年FRANKLIN FINANCIAL SERVICES CORP的营收复合增速更高（14.6% vs -12.2%）
富兰克林金融服务公司（宾夕法尼亚州）是美国地区性银行控股企业，主要在宾夕法尼亚州展业，为个人消费者、本地中小企业及区域机构客户提供存贷款、按揭融资、财富管理等综合零售及商业银行服务。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FRAF vs LAB — 直观对比
营收规模更大
FRAF
是对方的1.2倍
$19.6M
营收增速更快
FRAF
高出63.0%
-11.5%
净利率更高
FRAF
高出203.3%
-177.4%
两年增速更快
FRAF
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.3M | $19.6M |
| 净利润 | $6.0M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 32.1% | -168.5% |
| 净利率 | 25.9% | -177.4% |
| 营收同比 | 51.5% | -11.5% |
| 净利润同比 | 1140.7% | -28.8% |
| 每股收益（稀释后） | $1.35 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRAFLAB
| Q4 25 | $23.3M | — | ||
| Q3 25 | $23.0M | $19.6M | ||
| Q2 25 | $22.3M | $21.8M | ||
| Q1 25 | $20.2M | $40.8M | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $19.5M | $22.1M | ||
| Q2 24 | $18.6M | $22.5M | ||
| Q1 24 | $17.7M | $45.5M |
净利润FRAFLAB
| Q4 25 | $6.0M | — | ||
| Q3 25 | $5.4M | $-34.7M | ||
| Q2 25 | $5.9M | $-33.5M | ||
| Q1 25 | $3.9M | $-26.0M | ||
| Q4 24 | $487.0K | — | ||
| Q3 24 | $4.2M | $-26.9M | ||
| Q2 24 | $3.0M | $-45.7M | ||
| Q1 24 | $3.4M | $-32.2M |
毛利率FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率FRAFLAB
| Q4 25 | 32.1% | — | ||
| Q3 25 | 28.9% | -168.5% | ||
| Q2 25 | 32.8% | -118.1% | ||
| Q1 25 | 23.9% | -80.8% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 26.2% | -120.9% | ||
| Q2 24 | 19.8% | -134.5% | ||
| Q1 24 | 22.6% | -132.2% |
净利率FRAFLAB
| Q4 25 | 25.9% | — | ||
| Q3 25 | 23.3% | -177.4% | ||
| Q2 25 | 26.4% | -153.7% | ||
| Q1 25 | 19.4% | -63.8% | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 21.6% | -122.0% | ||
| Q2 24 | 16.3% | -203.3% | ||
| Q1 24 | 18.9% | -70.6% |
每股收益（稀释后）FRAFLAB
| Q4 25 | $1.35 | — | ||
| Q3 25 | $1.19 | $-0.09 | ||
| Q2 25 | $1.32 | $-0.09 | ||
| Q1 25 | $0.88 | $-0.07 | ||
| Q4 24 | $0.13 | — | ||
| Q3 24 | $0.95 | $-0.07 | ||
| Q2 24 | $0.66 | $-0.12 | ||
| Q1 24 | $0.77 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $127.7M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $175.2M | $399.7M |
| 总资产 | $2.2B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FRAFLAB
| Q4 25 | $127.7M | — | ||
| Q3 25 | $188.1M | $129.4M | ||
| Q2 25 | $207.8M | $158.6M | ||
| Q1 25 | $225.0M | $150.9M | ||
| Q4 24 | $203.6M | — | ||
| Q3 24 | $236.3M | $210.6M | ||
| Q2 24 | $179.7M | $269.8M | ||
| Q1 24 | $182.6M | $287.1M |
总债务FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益FRAFLAB
| Q4 25 | $175.2M | — | ||
| Q3 25 | $166.3M | $399.7M | ||
| Q2 25 | $157.4M | $424.5M | ||
| Q1 25 | $151.4M | $454.6M | ||
| Q4 24 | $144.7M | — | ||
| Q3 24 | $149.9M | $489.3M | ||
| Q2 24 | $136.8M | $510.3M | ||
| Q1 24 | $134.2M | $577.3M |
总资产FRAFLAB
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.3B | $539.6M | ||
| Q2 25 | $2.3B | $557.0M | ||
| Q1 25 | $2.3B | $579.6M | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | $681.5M | ||
| Q2 24 | $2.0B | $708.7M | ||
| Q1 24 | $2.0B | $777.7M |
负债/权益比FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.4M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | 4.21× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FRAFLAB
| Q4 25 | $25.4M | — | ||
| Q3 25 | $8.3M | $-22.2M | ||
| Q2 25 | $5.1M | $-20.7M | ||
| Q1 25 | $8.8M | $-30.3M | ||
| Q4 24 | $21.8M | — | ||
| Q3 24 | $7.8M | $-27.9M | ||
| Q2 24 | $2.4M | $-39.0M | ||
| Q1 24 | $7.3M | $-62.5M |
自由现金流FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度FRAFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率FRAFLAB
| Q4 25 | 4.21× | — | ||
| Q3 25 | 1.55× | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | 2.25× | — | ||
| Q4 24 | 44.67× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 0.80× | — | ||
| Q1 24 | 2.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRAF
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
